| No fish oil supplementation | Fish oil supplementation | p-value for interaction | ||||||
---|---|---|---|---|---|---|---|---|---|
N | Mean Difference | 95% CI | p-value | N | Mean Difference | 95% CI | p-value | Â | |
log (FEV1 pre bronchodilator (L)) | 154 | −0.04 | −0.09−0.01 | 0.083 | 147 | −0.04 | −0.08−0.01 | 0.100 | 0.760 |
log (FEV1 post bronchodilator (L)) | 151 | − 0.03 | − 0.08−0.01 | 0.150 | 146 | −0.03 | − 0.08−0.02 | 0.188 | 0.808 |
log (FVC pre bronchodilator (L)) | 154 | −0.05 | −0.10−0.01 | 0.102 | 147 | −0.03 | −0.08−0.01 | 0.171 | 0.854 |
log (FVC post bronchodilator (L)) | 151 | −0.03 | −0.08−0.03 | 0.306 | 146 | −0.01 | −0.06−0.04 | 0.641 | 0.950 |
FEV1/FVC ratio pre bronchodilator | 154 | −0.05 | −0.10−0.00 | 0.037 | 147 | −0.03 | −0.07−0.01 | 0.126 | 0.932 |
FEV1/FVC ratio post bronchodilator | 151 | −0.04 | −0.08−0.01 | 0.102 | 146 | −0.03 | −0.08−0.01 | 0.175 | 0.908 |
pre Peak Expiratory Flow (PEF) | 154 | −0.05 | −0.10−0.00 | 0.073 | 147 | −0.03 | −0.07−0.02 | 0.237 | 0.903 |
post Peak Expiratory Flow (PEF) | 151 | −0.03 | −0.07−0.02 | 0.240 | 146 | −0.01 | −0.05−0.03 | 0.727 | 0.795 |
Pre forced expiratory flow at 50% vital capacity (FEF50) | 154 | 0 | −0.02−0.01 | 0.623 | 147 | −0.01 | −0.02−0.01 | 0.549 | 0.935 |
Post forced expiratory flow at 50% vital capacity (FEF50) | 151 | −0.01 | −0.02−0.01 | 0.349 | 146 | −0.02 | −0.04−0.00 | 0.022 | 0.408 |
Pre forced expiratory flow at mid-expiratory phase (FEF25–75) | 102 | 5.30 | −6.24−16.85 | 0.364 | 99 | −0.32 | −14.53−13.88 | 0.964 | 0.386 |
Post forced expiratory flow at mid-expiratory phase (FEF25–75) | 100 | 6.23 | −6.04−18.50 | 0.316 | 98 | −0.49 | −14.22−13.24 | 0.944 | 0.410 |